This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (240)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuropathology  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Emmanuel Mignot, MD, PhD; Gert Jan Lammers, MD, PhD; Beth Ripley, MS; Michele Okun, MA; Sonia Nevsimalova, MD, PhD; Sebastiaan Overeem, MS; Jitka Vankova, MD; Jed Black, MD; John Harsh, PhD; Claudio Bassetti, MD; Harald Schrader, MD; Seiji Nishino, MD, PhD

Arch Neurol. 2002;59:1553-1562.

Context  Narcolepsy, a neurological disorder affecting 1 in 2000 individuals, is associated with HLA-DQB1*0602 and low cerebrospinal fluid (CSF) hypocretin (orexin) levels.

Objectives  To delineate the spectrum of the hypocretin deficiency syndrome and to establish CSF hypocretin-1 measurements as a diagnostic tool for narcolepsy.

Design  Diagnosis, HLA-DQ, clinical data, the multiple sleep latency test (MSLT), and CSF hypocretin-1 were studied in a case series of patients with sleep disorders from 1999 to 2002. Signal detection analysis was used to determine the CSF hypocretin-1 levels best predictive for International Classification of Sleep Disorders (ICSD)–defined narcolepsy (blinded criterion standard). Clinical and demographic features were compared in narcoleptic subjects with and without low CSF hypocretin-1 levels.

Setting  Sleep disorder and neurology clinics in the United States and Europe, with biological testing performed at Stanford University, Stanford, Calif.

Participants  There were 274 patients with narcolepsy; hypersomnia; obstructive sleep apnea; restless legs syndrome; insomnia; and atypical hypersomnia cases such as familial cases, narcolepsy without cataplexy or without HLA-DQB1*0602, recurrent hypersomnias, and symptomatic cases (eg, Parkinson disease, depression, Prader-Willi syndrome, Niemann-Pick disease type C). The subject group also included 296 controls (healthy and with neurological disorders).

Intervention  Venopuncture for HLA typing, lumbar puncture for CSF analysis, primary diagnosis using the International Classification of Sleep Disorders, Stanford Sleep Inventory for evaluation of narcolepsy, and sleep recording studies.

Main Outcome Measures  Diagnostic threshold for CSF hypocretin-1, HLA-DQB1*0602 positivity, and clinical and polysomnographic features.

Results  HLA-DQB1*0602 frequency was increased in narcolepsy with typical cataplexy (93% vs 17% in controls), narcolepsy without cataplexy (56%), and in essential hypersomnia (52%). Hypocretin-1 levels below 110 pg/mL were diagnostic for narcolepsy. Values above 200 pg/mL were considered normal. Most subjects with low levels were HLA-DQB1*0602–positive narcolepsy-cataplexy patients. These patients did not always have abnormal MSLT. Rare subjects without cataplexy, DQB1*0602, and/or with secondary narcolepsy had low levels. Ten subjects with hypersomnia had intermediate levels, 7 with narcolepsy (often HLA negative, of secondary nature, and/or with atypical cataplexy or no cataplexy), and 1 with periodic hypersomnia. Healthy controls and subjects with other sleep disorders all had normal levels. Neurological subjects had generally normal levels (n = 194). Intermediate (n = 30) and low (n = 3) levels were observed in various acute neuropathologic conditions.

Conclusions  Narcolepsy-cataplexy with hypocretin deficiency is a genuine disease entity. Measuring CSF hypocretin-1 is a definitive diagnostic test, provided that it is interpreted within the clinical context. It may be most useful in cases with cataplexy and when the MSLT is difficult to interpret (ie, in subjects already treated with psychoactive drugs or with other concurrent sleep disorders).

From the Center for Narcolepsy, Stanford University, Stanford, Calif (Drs Mignot, Black, Nishino, and Mss Ripley and Okun); the Department of Neurology and Clinical Neurophysiology, Leiden University Medical Center, Leiden, the Netherlands (Dr Lammers and Mr Overeem); the Department of Neurology, Charles University, Prague, Czech Republic (Drs Nevsimalova and Vankova); University of Southern Mississippi, Hattiesburg (Dr Harsh); the Department of Neurology, Zürich University Hospital, Zürich, Switzerland (Dr Bassetti); and the Department of Neurology, Trondheim University Hospital, Trondheim, Norway (Dr Schrader).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency
Knudsen et al.
Brain 2010;:awp320v1-awp320.
ABSTRACT | FULL TEXT  

Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia
Compta et al.
Brain 2009;132:3308-3317.
ABSTRACT | FULL TEXT  

Psychological health in central hypersomnias: the French Harmony study
Dauvilliers et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:636-641.
ABSTRACT | FULL TEXT  

Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward System
Tsujino and Sakurai
Pharmacol. Rev. 2009;61:162-176.
ABSTRACT | FULL TEXT  

The Involvement of Hypothalamic Sleep Pathways in General Anesthesia: Testing the Hypothesis Using the GABAA Receptor {beta}3N265M Knock-In Mouse
Zecharia et al.
J. Neurosci. 2009;29:2177-2187.
ABSTRACT | FULL TEXT  

Narcolepsy and Idiopathic Hypersomnia
Avidan
ACCP Sleep Med Brd Rev 2009;4:45-62.
FULL TEXT  

Genetic and Immunologic Aspects of Sleep Disorders
Parish
ACCP Sleep Med Brd Rev 2009;4:271-286.
FULL TEXT  

Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)
Baier et al.
Brain 2008;131:2734-2741.
ABSTRACT | FULL TEXT  

Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis
Knudsen et al.
Mult Scler 2008;14:734-738.
ABSTRACT  

Rapid Eye Movement Sleep Disturbances in Huntington Disease
Arnulf et al.
Arch Neurol 2008;65:482-488.
ABSTRACT | FULL TEXT  

Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy
Schwartz et al.
Brain 2008;131:514-522.
ABSTRACT | FULL TEXT  

The hypocretin neurotransmission system in myotonic dystrophy type 1
Ciafaloni et al.
Neurology 2008;70:226-230.
ABSTRACT | FULL TEXT  

Hypocretin/Orexin: A Molecular Link Between Sleep, Energy Regulation, and Pleasure
Ganjavi and Shapiro
J. Neuropsychiatry Clin. Neurosi. 2007;19:413-419.
ABSTRACT | FULL TEXT  

REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVEL
Dauvilliers et al.
Neurology 2007;69:1300-1301.
FULL TEXT  

Hypocretin (orexin) loss in Parkinson's disease
Fronczek et al.
Brain 2007;130:1577-1585.
ABSTRACT | FULL TEXT  

Hypocretin (orexin) cell loss in Parkinson's disease
Thannickal et al.
Brain 2007;130:1586-1595.
ABSTRACT | FULL TEXT  

Obesity, migraine, and chronic migraine: Possible mechanisms of interaction
Bigal et al.
Neurology 2007;68:1851-1861.
ABSTRACT | FULL TEXT  

In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1
Friedman et al.
Neurology 2007;68:793-794.
FULL TEXT  

Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder
Stiasny-Kolster et al.
Brain 2007;130:442-449.
ABSTRACT | FULL TEXT  

Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: Case study
Rojas-Marcos et al.
Neuro Oncology 2007;9:75-77.
ABSTRACT | FULL TEXT  

Hypocretin/Orexin Overexpression Induces An Insomnia-Like Phenotype in Zebrafish
Prober et al.
J. Neurosci. 2006;26:13400-13410.
ABSTRACT | FULL TEXT  

Regulation of Hypocretin (Orexin) Expression in Embryonic Zebrafish
Faraco et al.
J. Biol. Chem. 2006;281:29753-29761.
ABSTRACT | FULL TEXT  

Hypersomnias of central origin.
Young and Silber
Chest 2006;130:913-920.
ABSTRACT | FULL TEXT  

Orexins, energy balance, temperature, sleep-wake cycle
Szekely
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006;291:R530-R532.
FULL TEXT  

Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults
Mignot et al.
Brain 2006;129:1609-1623.
ABSTRACT | FULL TEXT  

Narcolepsy with Cataplexy in Early Childhood
Hayes
CLIN PEDIATR 2006;45:361-363.
ABSTRACT  

Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
Baumann et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:402-404.
ABSTRACT | FULL TEXT  

Kleine-Levin syndrome: a systematic review of 186 cases in the literature
Arnulf et al.
Brain 2005;128:2763-2776.
ABSTRACT | FULL TEXT  

Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barre syndrome
Cochen et al.
Brain 2005;128:2535-2545.
ABSTRACT | FULL TEXT  

Narcolepsy: Selective hypocretin (orexin) neuronal loss and multiple signaling deficiencies
Bassetti
Neurology 2005;65:1152-1153.
FULL TEXT  

Concomitant loss of dynorphin, NARP, and orexin in narcolepsy
Crocker et al.
Neurology 2005;65:1184-1188.
ABSTRACT | FULL TEXT  

Narcolepsy and Syndromes of Central Nervous System-Mediated Sleepiness
Black et al.
Focus 2005;3:585-597.
FULL TEXT  

The Number of Hypothalamic Hypocretin (Orexin) Neurons Is Not Affected in Prader-Willi Syndrome
Fronczek et al.
J. Clin. Endocrinol. Metab. 2005;90:5466-5470.
ABSTRACT | FULL TEXT  

Orexin loss in Huntington's disease
Petersen et al.
Hum Mol Genet 2005;14:39-47.
ABSTRACT | FULL TEXT  

Dissociation in circadian rhythms in a pseudohypersomnia form of fatal familial insomnia
Dauvilliers et al.
Neurology 2004;63:2416-2418.
ABSTRACT | FULL TEXT  

CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders
Arii et al.
Neurology 2004;63:2440-2442.
FULL TEXT  

Narcolepsy With Cataplexy
Krahn and Gonzalez-Arriaza
Am. J. Psychiatry 2004;161:2181-2184.
FULL TEXT  

In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients
Lodi et al.
Neurology 2004;63:1513-1515.
ABSTRACT | FULL TEXT  

Narcolepsy and excessive daytime sleepiness
Zeman et al.
BMJ 2004;329:724-728.
FULL TEXT  

REM Sleep Behavior Disorder in Parkinson's Disease and Dementia with Lewy Bodies
Boeve et al.
J Geriatr Psychiatry Neurol 2004;17:146-157.
ABSTRACT  

Clinical analysis of anti-Ma2-associated encephalitis
Dalmau et al.
Brain 2004;127:1831-1844.
ABSTRACT | FULL TEXT  

Behavioral State Instability in Orexin Knock-Out Mice
Mochizuki et al.
J. Neurosci. 2004;24:6291-6300.
ABSTRACT | FULL TEXT  

CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies
Baumann et al.
Neurology 2004;62:2337-2337.
FULL TEXT  

A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1
Dauvilliers et al.
Neurology 2004;62:2137-2138.
FULL TEXT  

Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma
Castillo et al.
Neurology 2004;62:1909-1909.
FULL TEXT  

Expression of a Poly-Glutamine-Ataxin-3 Transgene in Orexin Neurons Induces Narcolepsy-Cataplexy in the Rat
Beuckmann et al.
J. Neurosci. 2004;24:4469-4477.
ABSTRACT | FULL TEXT  

Narcolepsy Caused by Acute Disseminated Encephalomyelitis
Gledhill et al.
Arch Neurol 2004;61:758-760.
ABSTRACT | FULL TEXT  

Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis
Overeem et al.
Neurology 2004;62:138-140.
ABSTRACT | FULL TEXT  

CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions
Dauvilliers et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1667-1673.
ABSTRACT | FULL TEXT  

CSF hypocretin-1 levels in restless legs syndrome
Stiasny-Kolster et al.
Neurology 2003;61:1426-1429.
ABSTRACT | FULL TEXT  

CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies
Nishino et al.
Neurology 2003;61:823-825.
ABSTRACT | FULL TEXT